See more : Danske Invest Fjernøsten Indeks (DKIFJIX.CO) Income Statement Analysis – Financial Results
Complete financial analysis of Orphazyme A/S (ORPHY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Orphazyme A/S, a leading company in the Biotechnology industry within the Healthcare sector.
- C&D Property Management Group Co. Limited (2156.HK) Income Statement Analysis – Financial Results
- G-TECH Optoelectronics Corporation (3149.TW) Income Statement Analysis – Financial Results
- Shandong Huifa Foodstuff Co.,Ltd. (603536.SS) Income Statement Analysis – Financial Results
- Dynex Capital, Inc. (DX) Income Statement Analysis – Financial Results
- Shenzhen Colibri Technologies Co., Ltd. (002957.SZ) Income Statement Analysis – Financial Results
Orphazyme A/S (ORPHY)
About Orphazyme A/S
Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative rare diseases. The company offers heat stock proteins that focuses on the treatment of neurodegenerative diseases by harnessing the cell protective properties of the heat shock response, which protects cells from the accumulation of misfolded proteins, aggregated proteins, and dysfunctional lysosomes. Its lead candidate is the Arimoclomol, which is in clinical development for diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, and Inclusion Body Myositis. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.
Source: https://incomestatements.info
Category: Stock Reports